Third-Party Reimbursement for the Audiological Management of Patients Receiving Ototoxic Drugs Drug-related inner ear damage, or ototoxicity, results in auditory and/or vestibular dysfunction that is often permanent. Audiological management of patients receiving ototoxic drugs can minimize or prevent permanent ototoxic damage. At the very least, serial monitoring of hearing and balance function is necessary for making informed medical decisions regarding ... Article
Article  |   August 01, 2006
Third-Party Reimbursement for the Audiological Management of Patients Receiving Ototoxic Drugs
Author Affiliations & Notes
  • Steven C. White
    Health Care Economics and Advocacy, ASHA
  • Dawn Konrad-Martin
    Veterans Affairs Rehabilitation Research and Development Service, National Center for Rehabilitative Auditory Research, VA Medical Center, Portland, OR
    Department of Otolaryngology, Oregon Health & Science University, Portland, OR
Article Information
Hearing Disorders / Practice Management / Articles
Article   |   August 01, 2006
Third-Party Reimbursement for the Audiological Management of Patients Receiving Ototoxic Drugs
SIG 6 Perspectives on Hearing and Hearing Disorders: Research and Diagnostics, August 2006, Vol. 10, 16-17. doi:10.1044/hhd10.1.16
SIG 6 Perspectives on Hearing and Hearing Disorders: Research and Diagnostics, August 2006, Vol. 10, 16-17. doi:10.1044/hhd10.1.16
Drug-related inner ear damage, or ototoxicity, results in auditory and/or vestibular dysfunction that is often permanent. Audiological management of patients receiving ototoxic drugs can minimize or prevent permanent ototoxic damage. At the very least, serial monitoring of hearing and balance function is necessary for making informed medical decisions regarding the therapeutic treatment of these patients. Ototoxicity monitoring is not often mandated by hospital policy and is not standardized across practitioners, although ASHA guidelines for monitoring have existed for over a decade (1994) . Third-payer reimbursement is critical for maintaining an effective ototoxicity monitoring program. This article provides information intended as a resource for clinicians submitting claims for third-party reimbursement of audiological and vestibular testing related to ototoxicity monitoring. This information is not all-inclusive. Furthermore, reimbursement codes change periodically, and new drugs are frequently introduced to market. Conferring with a coding professional is recommended before submitting a claim if there is any question regarding the accuracy of a procedural or diagnostic code.
First Page Preview
First page PDF preview
First page PDF preview ×
View Large
Become a SIG Affiliate
Pay Per View
Entire SIG 6 Perspectives on Hearing and Hearing Disorders: Research and Diagnostics content & archive
24-hour access
This Issue
24-hour access
This Article
24-hour access
We've Changed Our Publication Model...
The 19 individual SIG Perspectives publications have been relaunched as the new, all-in-one Perspectives of the ASHA Special Interest Groups.